The past decade has seen great advances in the management of patients with HIV infection. The introduction of highly active antiretroviral therapy (HAART) has resulted in a decrease in opportunistic infections but the development of new clinical entities such as lipodystrophy and immune reconstitution illnesses. The use of investigations such as lipid profiles and dual energy X-ray absorptiometry (DEXA) scanning to assess lipodystrophy have been necessitated by these changes in the epidemic. Technological advances have resulted in new techniques such as viral resistance assays and single photon emission computed tomography (SPECT) scanning. The appropriate use of these investigations is subject to ongoing assessment.
AIDS and HIV infection in the United Kingdom: monthly report.Comm Dis Rep CDR Wkly2000; 10: 193–4
2.
DoddsJP, NardoneA, MerceyDE, JohnsonAM. Increase in high risk sexual behaviour among homosexual men, London 1996–8: cross sectional, questionnaire study.BMJ2000; 320: 1510–11.
3.
MartinIMC, IsonCA, and the London Gonococcal Working Group. Rise in gonorrhoea in London, UK.Lancet2000; 355: 623
4.
European Consensus Group of Hepatitis B Immunity.Are booster immunisations needed for lifelong hepatitis B immunity?Lancet2000; 255: 561–5
5.
EllerbrockTV, ChiassonMA, SunXW. Incidence of cervical squamous intraepithelial lesions in HIV-infected women.JAMA2000; 283: 1031–8.
6.
JohnsonF, McCooganE, SmartG. A population based, controlled study of the relation between HIV infection and neoplasia.Br J Obstet Gynaecol1994; 101: 986–91.
7.
MaimanM, FruchterRG, SerurE. Recurrent cervical intraepithelial neoplasia in human immunodeficiency virus-seropositive women.Obstet Gynecol1993; 82: 170–4.
8.
VernonS, HolmesKK, ReevesWC. Human papilloma virus infection and associated disease in persons infected with HIV.J Infect Dis1995; (suppl. 1): S121–4
9.
DelmasMC, LarsenC, van BenthemB. Cervical squamous intraepithelial lesion in HIV-infected women: prevalence, incidence and regression.AIDS2000; 14: 1775–84.
10.
SaagMS, HolodnityM, KuritzkesDR. HIV viral load markers in clinical practice.Nat Med1996; 2: 625–9.
11.
CoombsRW, WellesSL, HooperC. Association of plasma human immunodeficiency type 1 RNA level with risk of clinical progression in patients with advanced infection.J Infect Dis1996; 174: 704–12.
12.
PozniakA, GazzardBG, ChurchillD. British HIV association guidelines for the treatment of HIV-infected adults with antiretroviral therapy. Updated 28/1/200. On line at www.aidsmap.com
13.
FarzadeganH, HooverDR, AstemborskiJ. Sex differences in HIV-1 viral load and progression to AIDS.Lancet1998; 352: 1510–14.
14.
MooreRD, CheeverL, KerulyJC, ChaissonRE. Lack of sex difference in CD4 to HIV-1 RNA viral load.Lancet1999; 353: 463–4.
15.
KahnJO, WalkerBD. Acute human immunodeficiency virus type 1 infection.N Engl J Med1998; 339: 33–9.
16.
BuschMP, LeeLL, SattenGA. Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion; implications for screening of blood and tissue donors.Transfusion1995; 35: 91–7.
17.
BoagF, DeanR, HawkinsDA. Abnormalities of liver function during HIV seroconversion illness.Int J STD AIDS1992; 2: 46–8.
18.
Collaborative Group on AIDS Incubation and Survival.Time from HIV-1 seroconversion to AIDS and death before widespread use of highly active antiretroviral therapy: a collaborative re-analysis.Lancet2000; 355: 1131–7.
19.
HechtFM, GrantRM, PetropoulosCJ. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors.N Engl J Med1998; 339: 307–11.
MorcroftA, KatlamaC, JohnsonAM. AIDS across Europe, 1994–98: The EuroSIDA study.Lancet2000; 356: 291–6.
22.
MorcroftA, VellaS, BenfieldTL. Changing patterns of mortality across Europe in patients infected with HIV-1.Lancet2000; 353: 1725–30.
23.
ThiebautR, MorlatP, Jacqmin-GaddaH. Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment.AIDS2000; 14: 971–8.
24.
LedergerberB, EggerM, OpravilM. Clinical progression and virologic failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study.Lancet1999; 353: 863–8.
25.
FurtadoMR, CallawayDS, PhairJP. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy.N Engl J Med1999; 340: 1614–21.
26.
DurantJ, ClevenberghP, HalfonP. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial.Lancet1999; 353: 2195–200.
27.
BaxterJD, MayersDL, WentworthDN. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy.AIDS2000; 14: F83–93
28.
CohenC, HuntS, SensionM. Phenotypic resistance testing significantly improves response to therapy: a randomized controlled trial (VIRA3001) (Abstract 237). 7th Conference on Retroviruses and Opportunistic Infections. San Francisco 2000.
29.
HirschMS, Brun-VezinetF, D'AquilaR. Antiretroviral drug resistance testing in adult HIV-1 infection.JAMA2000; 283: 2417–26.
DurantJ, ClevenberghP, GarraffoR. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the VIRADAPT study.AIDS2000; 14: 1333–9.
32.
KastrissiosH, SuarezJR, HammerS. The extent of non-adherence in a large AIDS clinical trial using plasma dideoxynucleoside concentrations as a marker.AIDS1998; 12: 2305–11.
33.
SchneiderMME, BorleffsJCC, StolkRP, JaspersCAJJ, HoepelmanAIM. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1 infected patients treated with highly active antiretroviral therapy.Lancet1999; 353: 201–3.
34.
El-SadrWM, BurmanWJ, GrantLB. Discontinuation of prophylaxis against Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy.N Engl J Med2000; 342: 1085–92.
35.
CrookMA, MirN. Abnormal lipids and the acquired immunodeficiency syndrome: is there a problem and what should we do about it?Int J STD AIDS1999; 10: 353–6
36.
SafrinS, GrunfeldC. Fat redistribution and metabolic changes in patients with HIV infection.AIDS2000; 13: 2493–505.
37.
CarrA, SamarasK, ThorisdottirA, KaufmannGR, ChisholmDJ, CooperDA. Diagnosis, prediction and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study.Lancet1999; 353: 2093–9.
38.
MillerKD, JonesE, YanovskiJA, ShankarR, FeuersteinI, FalloonJ. Visceral abdominal-fat accumulation associated with the use of indinavir.Lancet1998; 351: 871–5.
39.
HirschtickRE, HansenNI, LavangeL. Bacterial pneumonia in persons infected with human immunodeficiency virus: pulmonary complications of HIV study group.N Engl J Med1995; 333: 845–51.
40.
Centers for Disease Control and Prevention.Surveillance for AIDS-defining opportunistic illnesses, 1992–1997.MMWR1999; 48(SS-2): 1–22
41.
GoodmanPC, GamsuG. Pulmonary radiographie findings in the acquired immunodeficiency syndrome.Postgrad Radiol1987; 7: 3–15.
42.
WehnerJH. Controlled utilization sputum analysis in the diagnosis of Pneumocystis carinii pneumonia.Chest1994; 105: 1770–4.
PerlmanDC, el-SadrWM, NelsonET. Variation of chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related immunosuppression: the Terry Beirn Community Programs for clinical research on AIDS (CPCRA).Clin Infect Dis1997; 25: 242–6.
45.
JonesBE, YoungSMM, AntoniskisD, DavidsonPT, KramerF, BarnesPF. Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection.Am Rev Respir Dis1993; 148: 1292–7.
46.
SharpstoneD, GazzardB. Gastrointestinal manifestations of HIV infection.Lancet1996; 348: 379–83.
47.
BlanshardC, GazzardBG. An algorithm for the investigation of diarrhoea in HIV infection.Gut1991; 32: A1225
48.
WilcoxCM, RabenneckL, FriedmanS. Malnutrition and cachexia, chronic diarrhoea and hepatobiliary disease in patients with human immunodeficiency virus infection.Gastroenterology1996; 111: 1724–52.
49.
KaplanLD. Clinical management of human immunodeficiency virus-associated non-Hodgkin's lymphoma.J Nat Cancer Inst Monogr1998; 23: 101–5.
50.
WhitcupSM. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy.JAMA2000; 283: 653–7.
51.
SandlerAS, KaplanLD. Diagnosis and management of systemic non-Hodgkin's lymphoma in HIV disease.Hem Oncol Clin N Am1996; 10: 1111–24.
